|Articles|November 14, 2018
CSF-1 drops demonstrate efficacy, safety in clinical studies for treatment of presbyopia
Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at OIS@AAO 2018 in Chicago.
Advertisement
Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at OIS@AAO 2018 in Chicago.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
UPDATE: STAAR postpones Alcon merger vote, Broadwood calls for removal of board members
2
VR and imaging advancements showcased at AAO 2025
3
Advancements in femtosecond laser technology benefit surgeons and patients
4
Topcon Healthcare seeks to advance company through acquisition and new investment
5













































.png)


